about
World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in RussiaPharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis.Daclatasvir/Asunaprevir/Beclabuvir (DCV-TRIO), All-Oral, Fixed-Dose Combination for Patients With Chronic HCV Genotype 1.World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015.Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.The analysis of immunophenotype of gastrin-producing tumors of the pancreas and gastrointestinal tract.Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.Effects of Multivitamin, Multimineral and Phytonutrient Supplementation on Nutrient Status and Biomarkers of Heart Health Risk in a Russian Population: A Randomized, Double Blind, Placebo Controlled Study.Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and SwedenTreatment of Helicobacter pylori positive duodenal ulcersGastric cancer screening in selected population of Moscow region: retrospective evaluationOral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trialUnusual oral mucosa damage during telaprevir treatment of chronic hepatitis CWorld Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013[The role of dietary diversity in the formation of syndrome intestinal bacterial overgrowth][Features of nutrition pattern of patients with small intestinal bacterial overgrowth resistant to therapy]Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
P50
Q34662402-B5252B19-985C-4809-9652-20D5CF385107Q36615197-34BA3747-4F13-431A-9805-4F308B672D13Q37428608-9854FB87-077F-4D13-B82D-FEDD9DA21FD9Q38859479-EC72AA01-E47F-4F55-A007-1A4DBC11D8A5Q38953335-E2751EB9-863F-44DC-A40A-7C6A869610F3Q39115914-75B69225-6132-4D76-B3EC-0E39AC09573EQ40466129-EB0DC6F2-53AE-4E58-8B4F-A4C273B1236DQ40500696-E98750BD-2877-4E67-A36B-B4C68CAD87FEQ44080544-9686575B-63E4-4D5D-A082-0ED03BBB5059Q44635878-EAA2C553-CF4B-4B74-9A2F-C0806B842C56Q47572592-356E19F4-ACBD-4487-9D2A-9BC13E256FAAQ48166360-974970EC-57E2-47D4-AE7E-C219BCC3A1EDQ55065074-EB727E41-E840-4FDD-B8C3-A7596F3C9903Q59349467-F9907169-040C-4626-8A05-11C1645ACCA0Q68095293-630887C3-D491-4F74-86F2-AC6AB6DB5341Q77831336-43CA28F2-658F-47F2-A760-B7340B79667BQ82779804-05C1A019-508C-4709-B93A-D923F7A156CFQ86923203-E1E0C2A1-D358-4306-8FE7-4D0295F70DB6Q87247208-5E966107-C8A0-434D-811D-F3C500C4141AQ89829190-F30D3290-5FF9-472D-A28E-ADCF2A809CE8Q91226956-1FA74337-172C-4E18-8EDB-686E02C0DDECQ94526219-5B283344-2ECF-4D4A-8D9F-169ED63C424F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vasily Isakov
@ast
Vasily Isakov
@en
Vasily Isakov
@es
Vasily Isakov
@nl
type
label
Vasily Isakov
@ast
Vasily Isakov
@en
Vasily Isakov
@es
Vasily Isakov
@nl
prefLabel
Vasily Isakov
@ast
Vasily Isakov
@en
Vasily Isakov
@es
Vasily Isakov
@nl
P106
P1153
7102480906
P31
P496
0000-0002-4417-8076